Taro Pharmaceutical Industries Ltd. and Travere Therapeutics, Inc.: A Detailed Gross Profit Analysis

Taro vs. Travere: A Decade of Diverging Profits

__timestampTaro Pharmaceutical Industries Ltd.Travere Therapeutics, Inc.
Wednesday, January 1, 201458000600027632226
Thursday, January 1, 201567658500097707000
Friday, January 1, 2016778966000129037000
Sunday, January 1, 2017671251000151332000
Monday, January 1, 2018463508000158719000
Tuesday, January 1, 2019445724000170104000
Wednesday, January 1, 2020399725000192195000
Friday, January 1, 2021296656000220706000
Saturday, January 1, 2022293122000204426000
Sunday, January 1, 2023268323000133788000
Monday, January 1, 2024304979000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Taro vs. Travere

In the ever-evolving pharmaceutical landscape, Taro Pharmaceutical Industries Ltd. and Travere Therapeutics, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Taro's gross profit peaked in 2016, reaching nearly 780 million, before experiencing a steady decline, dropping by approximately 66% by 2023. In contrast, Travere's journey has been one of growth, with gross profit increasing by over 380% from 2014 to 2022, despite a slight dip in 2023.

Key Insights

  • Taro's Decline: Taro's gross profit saw a significant downturn post-2016, highlighting potential challenges in market dynamics or operational efficiencies.
  • Travere's Growth: Travere's consistent upward trend until 2022 underscores its strategic advancements and market penetration.

As we look to 2024, the absence of data for Travere suggests a potential shift or strategic pivot, leaving industry watchers eager for updates.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025